169 related articles for article (PubMed ID: 35529850)
1. Characterization of Two TNF-Related Subtypes Predicting Infliximab Therapy Responses in Crohn's Disease.
Ye C; Zhu S; Yuan J
Front Immunol; 2022; 13():871312. PubMed ID: 35529850
[TBL] [Abstract][Full Text] [Related]
2. Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis.
Lacruz-Guzmán D; Torres-Moreno D; Pedrero F; Romero-Cara P; García-Tercero I; Trujillo-Santos J; Conesa-Zamora P
Eur J Clin Pharmacol; 2013 Mar; 69(3):431-8. PubMed ID: 22960943
[TBL] [Abstract][Full Text] [Related]
3. Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.
Medvecz M; Kiss N; Hársing J; Kuroli E; Hegede G; Csomor J; Kárpáti S; Marschalkó M
Acta Dermatovenerol Croat; 2019 Sep; 27(3):202-204. PubMed ID: 31542070
[TBL] [Abstract][Full Text] [Related]
4. Constructing models for Crohn's disease diagnosis and prediction of infliximab non-response based on angiogenesis-related genes.
Zheng C; Chen X; Ke Y; Xu X; Wu C; Jiang L
Front Immunol; 2024; 15():1239496. PubMed ID: 38343536
[TBL] [Abstract][Full Text] [Related]
5. Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn's disease patients.
Lykowska-Szuber L; Walczak M; Stawczyk-Eder K; Krela-Kazmierczak I; Eder P; Zakerska-Banaszak O; Dobrowolska A; Skrzypczak-Zielinska M
J Appl Genet; 2023 Dec; 64(4):759-768. PubMed ID: 37658984
[TBL] [Abstract][Full Text] [Related]
6. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
7. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
[TBL] [Abstract][Full Text] [Related]
8. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease.
Salvador-Martín S; López-Cauce B; Nuñez O; Laserna-Mendieta EJ; García MI; Lobato E; Abarca-Zabalía J; Sanjurjo-Saez M; Lucendo AJ; Marín-Jiménez I; Menchén LA; López-Fernández LA
Pharmacol Res; 2019 Nov; 149():104478. PubMed ID: 31605784
[TBL] [Abstract][Full Text] [Related]
9. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA Antisense Noncoding RNA in the INK4 Locus Correlates With Risk, Severity, Inflammation and Infliximab Efficacy in Crohn's Disease.
Ge Q; Dong Y; Lin G; Cao Y
Am J Med Sci; 2019 Feb; 357(2):134-142. PubMed ID: 30665494
[TBL] [Abstract][Full Text] [Related]
11. A Remarkable Response of Granulomatous Hypophysitis to Infliximab in a Patient With a Background of Crohn's Disease-A Case Report.
Force BK; Vogel TP; Nguyen DM; Heck KA; Sebastian S; Takashima M; Yoshor D; Samson SL
Front Endocrinol (Lausanne); 2020; 11():350. PubMed ID: 32547497
[No Abstract] [Full Text] [Related]
12. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
13. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention.
Pagnini C; Cominelli F
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638616
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
15. Association of TRAP1 with infliximab-induced mucosal healing in Crohn's disease.
Park SH; Hong M; Lee HS; Ye BD; Hwang SW; Jung S; Baek J; Moon JW; Kim BM; Oh SH; Kim KM; Lee I; Im CN; Liu J; McGovern DPB; Yang SK; Song K
J Gastroenterol Hepatol; 2019 Dec; 34(12):2118-2125. PubMed ID: 31039275
[TBL] [Abstract][Full Text] [Related]
16. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
[TBL] [Abstract][Full Text] [Related]
17. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
Dideberg V; Théâtre E; Farnir F; Vermeire S; Rutgeerts P; De Vos M; Belaiche J; Franchimont D; Van Gossum A; Louis E; Bours V
Pharmacogenet Genomics; 2006 Oct; 16(10):727-34. PubMed ID: 17001292
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF Therapy Induces CD4+ T-Cell Production of IL-22 and Promotes Epithelial Repairs in Patients With Crohn's Disease.
Fang L; Pang Z; Shu W; Wu W; Sun M; Cong Y; Liu Z
Inflamm Bowel Dis; 2018 Jul; 24(8):1733-1744. PubMed ID: 29718341
[TBL] [Abstract][Full Text] [Related]
19. Plasma Oncostatin M, TNF-α, IL-7, and IL-13 Network Predicts Crohn's Disease Response to Infliximab, as Assessed by Calprotectin Log Drop.
Mateos B; Sáez-González E; Moret I; Hervás D; Iborra M; Cerrillo E; Tortosa L; Nos P; Beltrán B
Dig Dis; 2021; 39(1):1-9. PubMed ID: 32325460
[TBL] [Abstract][Full Text] [Related]
20. Monocytes from infliximab-resistant patients with Crohn's disease exhibit a disordered cytokine profile.
Gaiani F; Rotoli BM; Ferrari F; Barilli A; Visigalli R; Carra MC; de'Angelis GL; de'Angelis N; Dall'Asta V
Sci Rep; 2020 Jul; 10(1):12238. PubMed ID: 32699266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
